Yonkenafil is a phosphodiesterase type 5 (PDE5) inhibitor and can protect the neuronal networks from injury after a stroke. Yonkenafil can have a potential therapeutic effect on Alzheimer’s disease by modulating neurogenesis to improve cognitive function and improving the amyloid burden in mice